You are here
Screening, prognostic, predictive and diagnostic biomarkers. Non-invasive and tissue-based cancer biomarkers are available for licensing or collaborative development.
Over 1.3 million people worldwide are diagnosed with lung cancer each year and over a million die.Read more
The integrin avß6 is an exciting emerging target for both imaging and therapy across many common tumour types including pancreatic, breast, oesophagus, head and neck, skin, lung and ovarian.Read more